Although anti-inflammatory therapies can counter some of the effects of TGF-β1 in the CF airway epithelium in vitro [11,16], additional strategies may be required to improve the CFTR response to modulators in a TGF-β1 dominant inflammatory environment. This evidence concerns the gene CFTR and cystic fibrosis.